Products - Children and teenagers | Topic

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 33 products

Date | Title

Status: Topic selectionRemove ‘Status: Topic selection’ filter

Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years [ID6554]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TSID10639]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years [TSID11819]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years [TSID11887]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TSID10574]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TSID10722]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for children with severe atopic dermatitis [TSID10434]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TSID10085]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 6 months to 11 [TSID11806]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lebrikizumab for treating atopic dermatitis in children [TSID12133]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lebrikizumab for treating atopic dermatitis in children [TSID 12133_TSID 12135]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant [TS ID 11868]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Linaclotide acetate for treating functional constipation in people 6 to 17 years [TSID12125]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years [TSID11805]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
NEMOST growing domino for Neuromuscular early onset scoliosis with Risser 0 in first surgical intention
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Paediatric lymphatic interventions (mainly Percutaneous thoracic duct embolisation) for Chylothorax, chylous ascites, plastic bronchitis, chylopericardium, Chyluria, Protein losing enteropathy
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years [TSID12092]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 [TSID11827]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 [TSID11828]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sulthiame for treating self-limiting epilepsy with centrotemporal spikes in children TSID 12106
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vedolizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years [TSID12134]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Quality standards

Indicators

Get support from NICE

Learn how we evaluate technologies

Register your product

Find published and proposed evaluations

Our programmes

Get involved

What we do

Into practice

Who we are

Children and teenagers Products

Showing 33 products